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Semi-Parametrics Dose Finding Methods
Matthieu Clertant and John O’Quigley
Abstract
We describe a new class of dose finding methods to be used in early phase clinical
trials. Under some added parametric conditions the class reduces to the family
of continual reassessment method (CRM) designs. Under some relaxation of the
underlying structure the method is equivalent to the CCD, mTPI or BOIN classes
of designs. These latter designs are non-parametric in nature whereas the CRM
class can be viewed as being strongly parametric. The proposed class is char-
acterized as being semi-parametric since it corresponds to CRM with a nuisance
parameter. Performance is good, matching that of the CRM class and improving
on it in some cases. The structure allows theoretical questions to be more easily
investigated and to better understand how different classes of methods relate to
one another.
Semi-Parametric Dose Finding Methods
Clertant, M. and O'Quigley, J. 1
Université Pierre et Marie Curie, Paris, France
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method is equivalent to the CCD, mTPI or BOIN classes of designs. These latter designs are
non-parametric in nature whereas the CRM class can be viewed as being strongly parametric.
The proposed class is characterized as being semi-parametric since it corresponds to CRM with
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Introduction
The importance of early phase dose ﬁnding studies - so called Phase I and Phase I/II clinical
trials - is diﬃcult to overstate. This is particularly so in oncology where it is believed that
a signiﬁcant number of the more than ninety percent of failed large scale randomized clinical
trials can, to a more or lesser degree, be explained by an ineﬃcient or an inaccurate early
phase study. The recommended dose would have been either too high, and poorly tolerated,
or too low and, in consequence, unable to provide an adequate anti-tumour response. It
is widely recognized by statisticians and clinicians alike that the standard 3+3 dose ﬁnding
design (Storer, 1989) widely employed in Phase I trials is fatally ﬂawed and, in some sense, not
ﬁt for purpose. As a result the last twenty ﬁve years has seen considerable statistical research
into early phase designs that are more eﬃcient while simultaneously paying attention to the
ethical constraints required in the running of any such trial.
Diﬀerent approaches divide themselves into two classes; the ﬁrst - examples include the
3+3 and the Rolling Six (Skolnik et al., 2008) - are called algorithmic designs since no modeling
takes place and the escalation, de-escalation rules are determined solely as a function of some
set of the most recent observations. They have a Markov property, sometimes referred to in
this context as a lack-of-memory property. The second class of designs are called model-based
designs. Their motivation is to impose greater structure on the observations in order to increase
1Address for correspondence: Matthieu Clertant or John O'Quigley, LSTA, Université Pierre et Marie Curie
Paris 6, 15-25, 4, place Jussieu 75005 Paris France
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the information obtained through sampling as well as to satisfy large sample convergence of
the recommended dose to the true MTD. Statistical properties such as almost sure convergence
are important in as much as, without such properties, it is diﬃcult to feel conﬁdent in the
solidity of any approach. At the same time, in real studies, sample sizes are often no more than
20 to 30 and so it is also crucial to have desirable ﬁnite sample properties such as coherence
(Cheung, 2005). Simulations, across broadly varying situations, have been a useful help in
developing methods. One clear advantage of the model-based designs is their ability to be
generalized to deal with more complex situations such as group heterogeneity, combination
therapies and toxicity attribution error.
The most well known of the model-based designs is the continual reassessment method
(CRM) introduced by O'Quigley, Pepe and Fisher (1990). The method has been very successful
but despite its now well known superior performance over the standard design, its use still lags
behind that of the standard design. One explanation for this is that many clinicians are not at
ease in using a method whose in-trial operating behaviour can not be immediately anticipated
as well as the fact that help in the form of an able bodied statistician is recommended. But
there are other statistical concerns (Azriel et al., 2011) that have led to the development of
many competing model-based approaches. Among these are EWOC (Babb et al., 1998), mTPI
(Ji et al., 2010) and BOIN (Liu and Yuan, 2015). Some authors have pointed out that the
conditions for almost sure convergence in Shen and O'Quigley (1996) are very restrictive, and
therefore not realistic. Cheung and Chappell (2002) and Azriel (2012) described ways to relax
these assumptions but the concerns still remain.
The CRM is based on a strong parametrisation of the regression function, so much so
that it is often described as an under parametrized model. Taking our cue from Cheung and
Chappell's work on the CRM, we introduce a semi-parametric characterization of the method
(Section 2). This characterization can also be viewed as a hierarchical Bayesian model having
as a ﬁrst level the main parameter of interest, the MTD itself, and, on a secondary level, families
of dose-toxicity curves constrained only by the location of the MTD. Within this framework
we can characterize several other current methods. We immediately gain some theoretical
advantages such as almost sure convergence to the Maximum Tolerated Dose (MTD) under
weaker conditions than those currently admitted. It is also much easier to anticipate large
sample behaviour in more general situations. The general structure allowed for by semi-
parametric models enables deeper study of the various methods currently available. Perhaps
no less importantly, we propose methods beneﬁting from improved asymptotics properties,
computationally very fast, which, for small samples, obtain as good and sometimes better
results than the CRM. Cheung and Chappell's characterization for the MTD as an interval
rather than a point paved the way to more realistic and achievable goals for dose ﬁnding
studies. These ideas are fundamental to our development here and, within this context, we
describe two central features of asymptotic behaviour. The ﬁrst is that of being sensitive
and the second that of being balanced. Under very wide and realistic dose-toxicity curves
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we show that the semi-parametric method exhibits desirable large sample behaviour regarding
these properties, and that this behaviour will indeed be reﬂected in commonly observed ﬁnite
samples. For any given situation, the large sample behaviour of the semi-parametric method
can be characterized by either almost sure convergence to the MTD or by inﬁnite oscillation
over two adjacent levels, the rates of visitation to either one of these levels being quantiﬁed
according to Kullback-Leibler divergence.
A user friendly program in R is available at address https://github.com/MatthieuMC/
SPM_project_01 .
1 Context of model-based designs
1.1 Basic set-up and notation
The statistical purpose is to estimate the root of an unknown dose-toxicity regression function
as observations are accumulated sequentially. The observations are the sequences: (Xn, Yn)n∈N.
At step n, the variable Xn is the dose selected from a range of available doses; D = {1, . . . ,m}
and the variable Yn is the observed binary response at this dose taking values {0, 1} : 1 for
a Dose Limiting Toxicity (DLT) and 0 otherwise. The conditional distribution of Yn given
Xn = d is Bernoulli with parameter βd, which implies that at each dose is associated a prob-
ability of toxicity independent of the way in which patients are selected into the study. The
range D has been chosen by clinical expertise so that the doses are ordered in terms of the
probability of toxic response.
Assumption 1.1. ∀n ∈ N, ∀d ∈ D, βd = P(Yn = 1|Xn = d) with β1 < . . . < βm .
Estimating the root of the regression function enables us to determine which dose among
those available in the range D suggests itself as having a probability of toxicity the closest
to some maximum amount α chosen by the investigators. This dose, noted d∗, is called
the MTD (maximum tolerated dose): d∗ = arg infd∈D |βd − α|. As patients are included
sequentially into the study, we suppose that all of the information contained in the sample,
(Xn1 , Y
n
1 ) = ((X1, . . . , Xn), (Y1, . . . , Yn)) is available to guide the selection of the dose Xn+1.
The ethical constraints of the study imposed by the clinical team encourages us to use all the
available information at each step in order to choose our best current estimate of the MTD as
the dose to be given to the following patient. The following deﬁnition (Cheung, 2005) describes
a property that any sensible design should have.
Deﬁnition 1.1. A method, M, is said to be coherent if the selection of the next dose given
the observed sample satisﬁes, for all d ∈ D and n ∈ N:
(Xn, Yn) = (d, 0) ⇒ M(Xn1 , Y n1 ) > d and (Xn, Yn) = (d, 1) ⇒ M(Xn1 , Y n1 ) 6 d ,
whereM(Xn1 , Y n1 ) denotes dose Xn+1 given (Xn1 , Y n1 ).
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The following assumption restricts attention to design based estimates that are adapted
to the accummulating observations.
Assumption 1.2. The current estimator of the method satisﬁes: M(Xn1 , Y n1 ) ∈ σ(Xn1 , Y n1 ) ,
where σ(Xn1 , Y
n
1 ) is the sigma-algebra generated by the sample.
Under this condition we are able to obtain classical asymptotic properties for frequentist
estimators β̂d,n deﬁned by:
β̂d,n =
n1d
n0d + n
1
d
=
n1d
nd
, where nid =
n∑
j=1
1{Xn=d,Yn=i} , i ∈ {0, 1} . (1)
Lemma 1.1. For all methods satisfying Assumption1.2, we have:
(i) Law of large numbers: β̂d,n −→
nd→+∞
βd , a.s.
(ii) Law of the iterated logarithm: for all βd ∈]0, 1[, with σd =
√
βd(1− βd), we have
lim sup
nd→+∞
√
nd
(
β̂d,n − βd
)
σd
√
2 log (log(nd))
= 1 and lim inf
nd→+∞
√
nd
(
β̂d,n − βd
)
σd
√
2 log (log(nd))
= −1 , a.s.
Proof. Part (i) is shown in Azriel, Mandel, and Rinott (2011, lemma 3) and Part (ii) in the
supplementary material.
This very general result provides no useful method in itself. Indeed, the event {nd → +∞} is
random depending on the vector β = (βd)d∈D and the chosen method. It is not immediately
clear how to obtain a consistent estimator of the MTD because we do not wish for each dose
to be observed inﬁnitely often. A good dose ﬁnding method will be all the more desirable as
it fulﬁlls two criteria:
(1) (TR, treatment): we would like the greatest possible number of patients to be treated at
and close to the MTD during the study.
(2) (PCS, percentage of correct selection): the method should lead us with high probability
to a correct determination of the MTD.
Reconciling and jointly optimising these two criteria creates speciﬁc diﬃculties for dose ﬁnding
studies. In this context it is worth recalling an impossibility theorem of Azriel et al. (2011)
that throws a useful light on the asymptotic results obtained here. These authors have shown
that no method exists that would, for all situations, allow the current estimator to be strongly
consistent. Only particular conﬁgurations with respect to the employed method result in
strong consistency.
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Theorem 1.1. Let M be a method satisfying Assumption1.2. A scenario β satisfying As-
sumption 1.1 exists such that:
Pβ(∃N : ∀n > N,M(Xn1 , Y n1 ) = d∗) < 1 .
Indeed, if the method recommends a single dose for n large enough, observations on competing
doses will cease. The information we have at these doses is ﬁnished and, of course, we may
then make an incorrect recommendation however large n.
Example 1.1. Let β = (0.05, 0.10, 0.20, 0.35, 0.55, 0.7) and α = 0.2 . Suppose that, for n
large enough, the design selects only dose 2 and the results for dose 3 are 2 DLT among 5
observations: β̂3,n = 0.4. In such circumstances, for all dose d 6= 2, the law of large numbers
will not apply to β̂d,n because the dose d is not inﬁnitely tested. The inaccuracy in the estimate
of toxicity related to dose 3 will not be overcome by increasing sample size. However, note that
the event {n2 → +∞} together with the assumption of monotonicity 1.1 allow us to eliminate
almost surely dose 1 from the candidate doses for being the MTD.
According to the Assumption 1.1, the two doses associated with toxic probabilities either
side of the target dose α are consecutive. It would then appear desirable as a large sample
property to concentrate experimentation on these doses. The class of methods introduced in
this article arise in a natural way from a critical analysis of the asymptotic properties of the
CRM (O'Quigley et al., 1990). This very general construct would allow us to include a wide
range of, at ﬁrst glance, diverse methods under a single general heading. This generalization
opens the way to make progress on two fronts; that of critical evaluation of the overall strategy
and that of more eﬃcient parameterization of particular existing methods alongside their
extensions when dealing with more complex clinical situations. In the rest of the article, we
study this in relation to the CRM. The proposed parametrisation enables us to reproduce
the global behavior of this method while obtaining better theoretical properties and allows
us to escape those diﬃculties consequent on poor model speciﬁcation (skeleton). In further
unpublished work we study more deeply this generalization as it relates to the CCD (Ivanova
et al., 2007), mTPI (Ji et al., 2010) and BOIN methods (Liu and Yuan, 2015), since the
semi-parametric structure leads to immediate improvements in all of these designs.
1.2 Parametric methods: Continual Reassesment Method
In this paragraph, we recall the principle features of the continual reassessment method. We
do this in a particular way which helps us to see how the new developments presented here
sit quite naturally within the basic framework of the CRM. The CRM method works by
approximating the dose-toxicity relationship d 7→ βd by a family of continuous functions of a
parameter a.
f : X × [A,B] → [0, 1]
(x, a) 7→ f(x|a) ,
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with [A,B] a ﬁnite interval and X a continuous set containing the range of doses D. We call
the family of functions (f(.|a))a∈[A,B] the model and the vector β the scenario (or reality).
Note that f(x|a) is the toxicity associated with the dose x, that is to say a model for the
probability of toxicity at dose x under parameter a. The following algorithm describes the
general working of CRM. In the Bayesian setting, G is the prior distribution of a and Gn
its posterior given the observations (Xn1 , Y
n
1 ) : Gn(da) ∝ Ln(a) × G(da), where Ln(a) =∏n
i=1f(Xi|a)Yi(1− f(Xi|a))1−Yi .
Step 1. Through the likelihood Ln, the current amount of information (X
n
1 , Y
n
1 ) is used to
update our estimate an of the parameter a or its posterior Gn.
Step 2. The estimator of the next dose, Xn+1 is obtained as a function of an or Gn.
Many possibilities are available for the second step. One approach is to calculate the
estimators of toxicity at each dose d ∈ D : β˜d,n = f(d|an) or β˜d,n = EGn [f(d, a)]. The
next dose is then the one whose estimated probability of toxicity is the closest to the desired
target: : Xn+1 = arg mind∈D|β˜d,n − α| . In order to set the context for the general semi-
parametric model, we propose a new estimator for step 2 which is based on the analysis
of Cheung and Chappell (2002). These authors provided an interpretation and insight into
poor model speciﬁcation by breaking down the parameter space: [A,B] = ∪d∈DHd, with
Hd = {a ∈ [A,B] : |f(d|a)− α| < |f(d′|a)− α|,∀d′ 6= d} . The set Hd is the parametric space
on which the model recommends dose d as the MTD. Asymptotic concerns together with the
sequential nature of CRM and the partition of the parameter space leads to the following
assumption. Let ad be such that: f(d|ad) = βd.
Assumption 1.3. ad∗ ∈ Hd∗ and ∀d ∈ D \ {d∗} , ad /∈ Hd .
Assuming that the functions f(.|a) are increasing for all a, Assumption 1.3 is equivalent to
the one under which Azriel (2012) shows the strong consistency of CRM. Theorem 1.1 rules
out the existence of a method providing almost sure convergence to the MTD regardless of the
circumstances. Indeed, Assumption 1.3 can not be checked because it requires control over the
reality expressing itself via the parametric elements ad (Cheung and Chappell, 2002, Figure
1) (Section 2.2, Figure 1). However, it does throw light on how the method works: the goal is
to identify the MTD among a small range of doses D, at the same time the CRM leans on the
estimation of a parameter in an inﬁnite set [A,B]. The method tries to ascertain the belonging
of this parameter to one of the sets of the family (Hd)d∈D. On the basis of this analysis, we
propose the following Bayesian estimator for the next dose (step 2) of CRM:
Xn+1 = arg max
d∈D
Gn(Hd) . (2)
The parametrization of the CRM can be expressed in terms of the MTD, θ. The prior Π is
a distribution on the range of doses such that for all θ ∈ D, we have: Π(θ) = G(Hθ). The
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family of priors Λ = (Λθ)θ∈D describe the dose-toxicity curve and we set Λθ(.) = G(.|Hθ).
This means that Λθ is the distribution G on the set Hθ. The prior G is then equal to the
probability measure Λ⊗ Π and the posterior Πn, following the observations (Xn1 , Y n1 ) can be
easily obtained by integrating the parameter of the dose-response curve for each θ : Πn(θ) ∝[∫
Ln(a)Λ(da|θ)
]
Π(θ) .
This hierarchical model being strictly equivalent to the Bayesian CRM, has no particular
value in this form. It does though allow a greater conceptual understanding of the distri-
butions Λ(.|θ) and their topological supports. Relaxing the structure of these distributions
and adding some ﬂexibility amounts to a model involving a nuisance parameter. This semi-
parametric setting provides methods that beneﬁt from improved asymptotic properties while
still conserving operating caracteristics for small sample size that are similar and in some cases
better to those of the CRM.
2 Semi-Parametric Models
2.1 General semi-parametric structure
Semi-parametric models (SPM) take as their starting point the direct modelling of the MTD
itself. This is formalized within the framework of Bayesian hierarchical models. It can also be
viewed in terms of model selection based on bayes factors. The hierarchical posterior allows us
to compare and evaluatem classes indexed by the main parameter of interest, the MTD. These
classes are structured by a prior referred to as a prior model (see Section 2.2). The initial
topological support of the prior is a broad one, corresponding to a non-informative situation.
We model the accumulating information via an m-tuple of Bernoulli laws. To this end
we introduce F an m-dimensional vector space of Bernoulli parameters covering a very wide
range of situations. Let q = (q1, . . . , qm) ∈ F , and qj the speciﬁc parameter corresponding to
dose j. The set F is partitioned in terms of the main parameter of interest, θ, which provides
us m distinct classes, each individual class containing an inﬁnite set of members sharing the
same MTD: F =
⋃
θ∈D
Fθ, with
Fθ = {q ∈ F : ∀j ∈ D , |qθ − α| 6 |qj − α| , j < θ ⇒ qj < α , j > θ ⇒ qj > α} . (3)
Given that θ takes on the value of some particular dose-level, then Fθ is the collection of dose-
toxicity curves having θ as the MTD. Lower levels in Fθ will necessarily have probabilities of
toxicity less than α, and conversely for higher levels. For all β in Fθ, the MTD is θ. The
vector (f(d, a))d∈D, with a ∈ Hθ (see the preceding section), is then included in Fθ. Indeed,
Fθ can be seen as a general extension of Hθ, such that F contains all the probability measure
in compliance with Assumption 1.1. From our point of view, determining the MTD θ can be
summarized by the following question. Which class is the most plausible one to have generated
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the data? The likelihood is:
Ln(q) =
∏
16i6n
(qXi)
Yi(1− qXi)1−Yi =
∏
16j6m
q
n1j
j (1− qj)n
0
j ,
where n1j is the number of toxicities at dose j and nj = n
1
j + n
0
j is the number of patients
treated at dose j. The set F is endowed with a probability measure Λ ⊗ Π such that Π is a
measure on D and the support of the measure Λ(.|θ) = Λθ(.) is included in the class Fθ. This
means that Π is a vector of m non-negative numbers summing up to 1 and Λ is a family of
distribution (Λθ)θ∈D indexed by the potential MTD, θ. The posterior distribution of θ given
(Xn1 , Y
n
1 ) is:
Πn(θ) = Π(θ|Xn1 , Y n1 ) ∝
∫ m∏
j=1
q
n1j
j (1− qj)n
0
jΛθ(dq)
Π(θ) . (4)
When we focus on the class Fθ, the posterior distribution of Λθ given (X
n
1 , Y
n
1 ) is: Λθ,n(dq) ∝∏
16j6mq
n1j
j (1− qj)n
0
jΛθ(dq) . By replacing this result in (4), we have:
Πn(θ) ∝
[∫
qYnXn(1− qXn)1−YnΛθ,n−1(dq)
]
Πn−1(θ) . (5)
Thus, each new observation leads ﬁrst to an update concerning the distribution Π by weighting
according to the expected value of the likelihood with respect to q conditioned by θ. In a second
step, this observation is used to update the probability measures Λθ on classes using Bayes
formula. In the following section, the family (Λθ)θ∈D will be called the prior model because
of the predictive model-like role it plays in sequential decision making. Fitting the model is
carried out by updating the prior Λθ. Finally, estimators of the MTD, θ̂ and of the toxicities
at dose j, β˜j , arise naturally and are the same we have already proposed and described for the
CRM:
θ̂n = arg max
θ∈D
Πn(θ) , β˜j = E(Λ⊗Π)n [qj ] =
m∑
θ=1
[∫
qjΛθ,n(dqj)
]
Πn(θ) . (6)
The general method might be summarized by the following points:
1. The current sample of observations (Xn1 , Y
n
1 ) is used to update the posterior Πn.
2. The estimator of the next dose is Xn+1 = θ̂n.
We introduce this semi-parametric class of models in the most usual situation of a Phase study
I summarized by Assumption 1.1. Under this assumption, a phase I study only deals with
a ﬁnite dimensional parameter. The term 'semi-parametric' refers to the methodology used
to build this structure. With the goal of determining the parameter of interest, the MTD,
a parametric model is extended by using nuisance parameters: when the MTD is dose 3,
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we do not have to estimate precisely q1 or q5. The proposed model covers the whole range of
scenarios, "which consists of all probability measures on the sample space for the observations"
(Bickel et al., 2005), as a non-parametric model does. The gain of ﬂexibility does not result in
a loss of simplicity. As all the parameters are readily available, the semi-parametric class of
models can be easily calibrated to reproduce the behavior of almost all of the designs currently
in use, including the algorithmic designs. This broad generalization allows us to investigate
theoretical questions, to more readily allow comparison between competing designs and to
look for ways to improve on any given design. Finally, the simplicity of calibration (see below)
together with the great range of possibilities suggest that the semi-parametric class of models
might be extended to more complicated situations in phase I involving inﬁnite dimensional
parameters: known examples being continuous grade of toxicities, heterogeneous populations,
combination studies and time-to-event toxicities.
2.2 A simple prior model speciﬁcation
A general calibration of SPM can be obtained as follows. We focus on the prior distributions
inside the classes, (Λθ)θ∈D. The support Sθ of the distribution Λθ will be included in Fθ and
will reﬂect locally the ordering of the parameters βj (Assumption 1.1). This local property
is suﬃcient to ensure that the design behaves in a sensible way. Indeed, after each new
observation or set of observations, the practitioner would like the method to indicate if the
dose appears too high, too low or acceptable. For this purpose, a natural partition of the
interval [0, 1] into 3 sets is introduced: I = [α−, α+], A = [α+, 1] and B = [0, α−]. The
support of distributions that we choose are in m dimension as the whole space of probability
measures for the observations. They are deﬁned according to the constraints on the MTD.
The Bernoulli parameters at each dose are considered as independent from the point of view
of a single class θ.
Assumption 2.1. (i) The support Sjθ of the marginal Λ
j
θ satisﬁes: S
j
θ = B when j < θ,
Sjθ = I when j = θ and S
j
θ = A when j > θ. We then have: Sθ = S
1
θ × . . .×Smθ ⊂ Fθ. (i) Λθ is
a product of unidimensionnal distributions at each doses: Λθ(dq) = Λ
1
θ(dq1)× . . .×Λmθ (dqm) .
The point (i) of the above assumption means that the support of qj depends on whether
j is above, below, or at the level of the MTD. In each circumstance the support reﬂects the
constraints on qj . The point (ii) is an independence assumption given θ. This independence
assumption could be relaxed although we have not studied this. Choosing the width of the
central interval is an important step in the parametrisation as it determines consistency (see
section 3). We propose here to use an interval centered in α. This leads the method to mimic
the CRM under the most common scenarios. Non-centered intervals can also be used which
provide more or less conservative results.
The direct calibration of the supports Sθ allows us to avoid those cases described in (Shen
and O'Quigley, 1996) that can result in non-convergence (see Figure 1 and scenario 8 in
9
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(a) CRM, G(.|H3) (see section 1.2)
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S3
(b) SPM, Λ3
Figure 1: Support of the dose-response curves for distributions G(.|H3) and Λ3. The broken
lines represent two kinds of poor speciﬁcation for CRM, the ﬂatter curve fails Assumption 1.3.
Table 3) as well as poor performance consequent upon poor model speciﬁcation (a slope in
the neighborhood of the MTD, Figure 1 and scenario 5 and 6 in Table 3). Note that the
independance of parameters qj 's in Assumption 2.1 is only valid conditionally given θ. This
means that all the information about dependence is captured by θ and is used to accomplish the
main goal of the study: determining the MTD, θ. Thus, the independance in the class implies
that the supports Sθ include locally decreasing scenarios of the dose-response phenomenom,
but all the scenarios in that class respect the mononicity between θ and the other doses.
Figure 2 (b) illustrates the dependence between the parameters qj 's and how we can describe
sub-models that include monotonicity restrictions. In this way, the family (Λθ)θ∈D can be
built from the model of CRM. As it is used to make inference in place of the usual parametric
model, the family (Λθ)θ∈D is called the prior model.
1 2 3 4 5
0.0
0.2
0.4
0.6
0.8
Doses
Tox
icit
y
(a) Regression curves of CRM, modes for SPM
1 2 3 4 5
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0.2
0.4
0.6
0.8
Doses
Tox
icit
y
(b) Sample under Λ2 and Λ3
Figure 2: Prior model built on the CRM model
The Beta distribution linked to the likelihood has a key role as it allows us to use conjugate
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priors. B(a + 1, b + 1) and BI(a + 1, b + 1) denote the Beta distribution and its restriction
to interval I with shape parameters a + 1 and b + 1. Let g be the following function: g :
[0, 1] × R2+ → [0, 1] , with g(x, a, b) = xa(1 − x)b . The density function of B(a + 1, b + 1)
is g(., a, b)/B(a + 1, b + 1), with B(a + 1, b + 1) =
∫ 1
0 g(x, a, b)dx. When conjugate priors
are used, the whole prior model can be summarized by a triplet [, (qθ)θ∈D, c]. The number 
belongs to [0, 1] and determines the centered interval. The vectors qθ ∈ [0, 1]m are the modes
of distributions Λθ. The positive real value c is the dispersion parameter of the distributions.
Uniform priors on the topological supports are updated so that,
Λθ ≈
θ−1∏
j=1
BB(cqθj+1, c(1−qθj )+1)×BI(cqθθ+1, c(1−qθθ)+1)×
m∏
j=θ+1
BA(cqθj+1, c(1−qθj )+1) (7)
In Figure 2 (b), the prior model is built by using a model f of CRM: qθ = [f(j, |αθ)]j∈D, with
f(d, αθ) = α (see Figure 2 (a)). All the parametrisations proposed in this article fulﬁll an
assumption about stochastic ordering on the prior model. At each moment of the trial, for
any dose j0, the marginal posterior Λ
j0
θ,n(.) should be stochastically greater than Λ
j0
θ′,n(.) when
θ is smaller than θ′ (see supplementary material, Section 2). In the setting of SPM, it is the
main argument needed to obtain the coherence property of Cheung (2005). The prior model
should respect a local order between the classes corresponding to the diﬀerent MTD, and not
inside one class.
Theorem 2.1. If the prior model satisﬁes 2.1 and the assumption about stochastical ordering
(supplementary material), then SPM is coherent (Deﬁnition 1.1).
This analysis throws a light on the natural similarities between the prior model and parametric
models which satisfy the monotonicity assumption.
2.3 Summary and illustration
We have q = (q1, . . . , qm) a possible dose-toxicity scenario, i.e., qj is the probability of toxicity
at dose j. Λ = (Λθ)θ∈D is a family of priors for q, indexed by θ, the parameter identifying the
MTD. Given the MTD, θ, Λθ is made up of only those vectors q for which we know the MTD
to be at dose θ. Π is the prior on the parameter θ, often a discrete uniform. The couple (Π,Λ)
then describes a hierarchical model where the ﬁrst level deals with the goal of the study, the
MTD itself, and the second level concerns the dose-response curve. Bayes formula is used for
obtaining the posterior Πn according to the data already observed (see Section 2.1, Equation
4). The next selected dose is chosen to be the most probable: Xn+1 = arg maxθ∈D Πn(θ). The
prior model (Λθ)θ∈D can be calibrated in such a way to avoid those diﬃculties that arise for the
parametric model as a result of misspeciﬁcation. Given θ, we assume independence between
the diﬀerent probabilities of toxicity, which means that each prior Λθ is the simple product of
his marginals Λjθ on each dose j (Section 2.2). Under this assumption, the next dose selected
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corresponds to the parameter θ that maximizes the product of the expected likelihood at each
doses weighted by the prior Π(θ) :
Xn+1 = arg max
θ∈D
Πn(θ) = arg max
θ∈D
 m∏
j=1
∫
Ln(qj)Λ
j
θ(dqj)
Π(θ) (8)
Our approach is based on the following two steps:
- Calibration of Λ: (a) A partition of the probability space of toxicities is used for
calibrating the marginal laws: B = [0, α − ], I = [α − , α + ] and A = [α + , 1].
(b) The marginals are chosen from the Beta family (conjugacy). (c) The support Sjθ
of the marginal Λjθ is restricted to one of the three preceding intervals according to the
following rules: if j < θ, the marginal has support limited to B, if j = θ, the marginal
has support limited to I and if j > θ, the marginal has support limited to A.
- Calibration of Π: This prior is a vector of probabilities on the range of doses. It can be
easily calibrated. When the clinician has no extra-information to provide on the location
of the MTD, a non-informative prior might be chosen, a discrete uniform being a natural
candidate. However, given that this prior will drive the early escalation behavior until
we encounter a DLT, it is appealing to note that, not only will this prior impact early
behavior but, we can calibrate the prior in such a way as to obtain the very behavior
we would like to see. Early escalation can be slowed down or speeded up by simple
calibration of this prior.
The following examples are based on a very simple parametrisation. The target is ﬁxed at
α = 0.2.
SPM (0.05,0,0,0): The value  is 0.05 such that I = [0.15, 0.25]. All the marginals are
uniform on their respective interval. The distribution Π is uniform on the range of doses.
SPM(0, 1/10, 1/3, 40) : The size of the centered interval is null: Λθθ is a constant random
variable in α, for all θ ∈ D. We set: j < θ ⇒ qjθ = 1/10, j > θ ⇒ qθj = 1/3 and c is equal to
40 (See Equation (7)). The distribution Π is uniform.
In Table 4, the overall performances are summarized. When escalating, skipping a dose is
not allowed as this is now a requirement in these kinds of designs. These designs are com-
putationally very fast. R codes are available from the authors on request or at address:
https://github.com/MatthieuMC/SPM_project_01.
3 Large sample theory
The interval I is centered on α: I = [α−;α+]. All of the results presented here remain valid
for a non symmetric interval. Theorem 1.1 states that if treatment in a sequential experiment
is determined by the current estimator of the MTD, then this estimator cannot be strongly
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consistent. However, setting  > 0, if we assume that one or more doses are close enough to
α with accuracy , then we shall obtain almost sure convergence of the design to this set of
doses. Conversely, if we assume that neither dose is close enough to the threshold, the current
estimator shall recommend alternatively the two doses with toxicities directly located on both
sides of α. We introduce the following technical assumption which leans on the regularity of
the prior model.
Assumption 3.1. Let Sθ and S
j
θ be the topological support of Λθ and Λ
j
θ. The following
conditions are valid except when Λθθ is a Dirac measure.
(a) For all j ∈ D, the marginal distribution Λjθ is absolutely continuous with respect to
Lebesgue measure and λjθ denotes its density function.
(b) There exist two numbers s and S in (0,∞), such that, for all (j, θ) ∈ D2, we have:
∀ qj ∈ Sjθ , s < λjθ(qj) < S .
When the density function can not be bound into the neighborhoods of 0 or 1, we can obtain
compliance with the preceding assumption by using uniform priors on the small intervals [0, δ[
and ]1− δ, 1]:
λjθ(qj) ∝
∫ δ
0
g(q, cqθj , c(1− qθj ))dq 1[0,δ[(qj) + g(qj , cqθj , c(1− qθj ))1[δ,α[(qj).
Moreover, from the point of view of proving consistency, this assumption deals only with
theoretical scenarios where there exist some doses which are never toxic and others which
are always toxic. The following two deﬁnitions characterize the asymptotic behavior of SPM:
-sensitivity is a property connected to indiﬀerence intervals. (Cheung and Chappell, 2002).
Deﬁnition 3.1. Let  > 0 et I = [α− ;α+ ]. We consider the collection of doses associated
with a toxicity belonging to I: E(I, β) = {j ∈ D : βj ∈ I} . A method, M, is called -
sensitive, if for all β such that E(I, β) 6= ∅, we have:
Pβ [∃N , ∀n > N :M(Xn1 , Y n1 ) ∈ E(I, β)] = 1 .
If the true situation is such that a unique dose is associated with a target in the interval I,
then a method that is -sensitive converges almost surely to the MTD. When no dose has a
target located within I, the SPM will assume an oscillating behavior between two doses with
toxicities either side of the target α.
Deﬁnition 3.2. The letter D˜ denotes the set of doses inﬁnitely observed:
D˜ = {j ∈ D : nj →
n→+∞ +∞} .
Let b (below) and a (above) be the two consecutive doses associated to toxicities either side of
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the target α. A method, M, is called -balanced, if for all β such that E(I, β) = ∅, we have:
D˜ = {a, b} , a.s.
We might view oscillation as a desirable property for designs whose aim is to locate some dose,
since, if it is not possible to obtain a method that converges almost surely in all circumstances
(Theorem 1.1), it is nonetheless natural to want to construct an estimator, on the basis of
observations, that is strongly consistent. As soon as a dose belongs to D˜, it becomes possible
to reliably estimate its associated toxicity and the MTD belongs to the set {a, b}, which is
the minimal set on which we need to have observation when the goal is that of determinating
almost surely the MTD.
Theorem 3.1. Under the Assumptions 2.1 and 3.1, SPM is -sensitive and -balanced (see
remark 1).
Proof. The proof is given in the supplementary material.
Remark 1. In this theorem, and its proof, we consider that there exists no dose j0 such that
βj0 equals α± , with  > 0. This assumption is made for the purpose of clarity in presenting
the results.
Large sample behavior of SPM is established by Theorem 3.1. In the case where E(I, β) is
non empty, the sequence of doses selected by SPM converges almost surely to one or more
elements belonging to E(I, β). In the case where E(I, β) is empty, the running estimate of
SPM oscillates between those doses either side of the indiﬀerence interval. The two asymptotic
properties of SPM are simultaneously complementary and antagonistic, since, whenever we
diminish the size of the interval I, we increase the set of circumstances where the method
is -balanced and we diminish the ones where it is -sensitive. Furthermore, the interval I
can be chosen as small as we wish without having an eﬀect on overall performance of the
method. In the case of the simple parametrisation SPM(0, 1/10, 1/3, 40) presented in section
2.3,  is zero, which aside from the case where a toxicity would equal α leads necessarily to
an oscillation. This oscillation, giving an approximation of the two toxicities, allows for us to
construct convergent estimators in all of the scenarios β:
θ˜n = arg min
j∈Dˆn
|α− β̂j,n| , (9)
where Dˆn is the set of the last two selected doses: Dˆn = {θ̂n, θ̂n′} , with n′ = max{j < n :
θ̂j 6= θ̂n} .
Corollary 3.1. Under the Assumptions 2.1 and 3.1, with  = 0, the estimator θ˜n converges
almost surely to the MTD.
Proof. In the case where  = 0, the SPM is -balanced, which amounts to saying that: Dˆn →
D˜ = {a, b} . The law of large numbers (Lemma1.1) leads to an immediate result.
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Strong consistency of the estimator based on isotonic regression of the observations could be
obtained in the same way. According to the impossibility theorem of Azriel et al. (2011), the
estimators which possess the property of strong consistency can not be the current estimator
given by the method. The consistency of these estimators, regardless of the scenario, is
possible because the adjacent doses a and b will be chosen inﬁnitely often by the running
estimator: na →∞ and nb →∞. In the case of a ﬁnite sample size, experimentation will be
spread over two doses and may give the impression of convergence if the observations on one
dose are close enough to the expected rate. The following corollary considers an asymptotic
characterization of the number of observations allocated to the dose a relative to the number
allocated to b. For this it is helpful to recall entropy and divergence. Two Bernoulli laws
P and Q, are denoted by their parameters p and q. The entropy of Q relative to P is:
H(q|p) = −p log(q) − (1 − p) log(1 − q) , with log 0 = −∞ et 0 × (−∞) = 0 ; we denote the
entropy of P : H(p) = H(p|p). The divergence of Kullbac-Leibler of P relative to Q is:
DKL(p||q) = H(q|p)−H(p) = p log(p
q
) + (1− p) log(1− p
1− q ) . (10)
For p ∈ [0, 1], the function DKL(p||.) is strictly decreasing on [0, p] and strictly increasing on
[p, 1] and its minimum in p is equal to 0.
Corollary 3.2. Under the Assumptions 2.1 and 3.1, when  = 0 and when at least one of the
toxicities βa and βb is diﬀerent from α, we have:
na
nb
−→
n→+∞
DKL(βb||α)
DKL(βa||α) , a.s.
Proof. The proof is given in the supplementary material.
In situations more general than those for well speciﬁed models, the Kullback-Leibler diver-
gence is often used as an appropriate distance measure between two probability laws. This
pseudo-distance is the natural tool to use when showing consistency for Bayesian or maximum
likelihood estimators. In this way, the running estimate for SPM oscillates between doses a
and b according to an asymptotic ratio that is inversely proportional to the pseudo-distance
of Kullback-Leibler between βa and βb at the chosen target: the greater the pseudo-distance
between βa and α relative to that between βb and α the more SPM will recommend the dose b
(and vice versa). The purpose of the following section is to highlight the practical performance
of the usual SPM through a comparison with the CRM.
4 Simulations
The CRM demonstrates good performance with respect to the following criteria: (PCS),
the percentage of correct selection at the ﬁnal recommendation and (TR), the percentage of
patients treated at the MTD. Here, we show that, if we so wish, the prior model of SPM can be
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calibrated in such a way as to reproduce this same performance across many scenarios. This
particular parametrisation is called SP-CRM. The simulations are carried out under a common
situation (α = 0.2, power model) where the CRM is considered as close to optimal under an
adaptative minimum-variance criterion (Tian, 2016, Theorem 1 and its interpretation).
Calibration
The target rate is ﬁxed at 0.20. The goal is to locate the MTD as one of 6 available doses.
There are 25 patients in each study. We make use of two stage CRM (O'Quigley and Shen,
1996) based on some lead-in rule until we observe the ﬁrst toxicity and then we use max-
imum likelihood. As proposed by Cheung (dfcrm documentation in the CRAN package),
the chosen skeleton is u = (0.05, 0.10, 0.20, 0.35, 0.50, 0.70) with Normal law for the prior
N (0, 1.342) together with the power model. Each cohort is of size one meaning that we es-
timate the dose after each patient. We include the classical restriction that no skipping is
allowed. For SP-CRM, the prior model veriﬁes 2.1 and Equation (7). It is summarized by
( = 0.015, (qθ)θ∈D, c = 48). The modes (qθ)θ∈D are chosen close to the model of the CRM,
as in Figure 2 a). They are given by Table 1. The law Π can be used as an alternative
Table 1: The modes of the prior model
qθj q
1
. q
2
. q
3
. q
4
. q
5
. q
6
.
q·1 0.20 0.12 0.02 0.01 0.00 0.00
q·2 0.29 0.20 0.07 0.05 0.00 0.00
q·3 0.42 0.36 0.20 0.08 0.02 0.00
q·4 0.57 0.48 0.35 0.20 0.09 0.01
q·5 0.69 0.62 0.50 0.34 0.20 0.04
q·6 0.82 0.78 0.70 0.58 0.44 0.20
way to reproduce any initial dose escalation and we are able to choose it so that the method
follows naturally a given increasing sequence of doses until we observe the ﬁrst toxicity. An
increasing sequence is denoted s = (s1, . . . , sk) with sk ∈ D. The modes and the dispersion
being ﬁxed, we deﬁne B(s) the set of distributions Π that produce the sequence s until the
ﬁrst observed toxicity: B(s) = {Π : Yj = 0, 1 6 j 6 k ⇒ Xj = sk, 1 6 j 6 k }. The law
Ps is the one minimizing the distance in the sense L2 between the uniform distribution U and
the closure of the convex set B(s): Ps = arg min||Π − U||2, for Π ∈ B(s). This law does not
belong to B(s), but there exist distributions in B(s) arbitrarily close to Ps. It is then possible
to ﬁnd an approximation as accurate as we wish of the least informative distribution belonging
to the closure of the set of measure providing the sequence (R codes available on request).
Table 2 provides such distributions accurate to 10−3 for diﬀerent sequences. These laws are
not normalized but this does not impact the posterior Πn. In the following simulations, the
distribution corresponding to the sequence d is used. The CRM also produces this sequence
while awaiting to observe the ﬁrst toxicity.
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Table 2: Prior Π, walk through the levels awaiting the ﬁrst observed toxicity.
Sequences without toxicity Π(1) Π(2) Π(3) Π(4) Π(5) Π(6)
a: 111222333444555666 1 0.832 0.482 0.346 0.194 0.103
b: 112233445566****** 1 0.913 0.663 0.554 0.392 0.272
c: 123456************ 1 0.999 0.910 0.883 0.787 0.709
d: 1234556*********** 1 0.999 0.910 0.883 0.787 0.604
5 10 15 20 25
1
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3
4
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Patients
Do
ses
Figure 3: An example of a sequence for SP-CRM, β = (0.01, 0.07, 0.10, 0.20, 0.40, 0.70); 4:
toxicity, ×: non-toxicity.
Model and prior model
Table 3 shows performance of SP-CRM when compared to the CRM according to the criteria
(PCS) and (TR) for 10 000 replications. The ﬁndings show very similar behavior for the ﬁrst
4 scenarios. When the data are generated exactly by the model being used for CRM (scenario
3), rather surprisingly, that does not appear to grant any advantage to the method and the SP-
CRM appears to suﬀer no handicap as a price to pay for the extra-ﬂexibility and adaptability
of its prior model. On the other hand, scenario 4 presents an interesting illustration in which
the CRM fails to satisfy the Assumption 1.3 and, as a result, does not possess the property
of convergence to the MTD. Despite this, for a trial of 25 patients, it is diﬃcult to observe
any theoretical advantage of SP-CRM over CRM. However, it is enough to slowly increase
sample size to observe this convergence diﬃculty manifesting itself in practice (see ﬁgure 4).
Increasing the number of patients included in the study fails to lead to improvement for
CRM. In contrast, the SP-CRM is -sensitive and the portion of the curve that is traced out
corresponds to almost sure convergence. In a real practical sense, as sample size increases,
SP-CRM does better and better. In some ways, for CRM we were fortunate in that the best
performance was already obtained around 25 subjects and increasing this number was not
rewarded by increased accuracy. Beyond that sample size the handicap begins to show itself.
In other scenarios, for instance 5 and 6, where the model speciﬁcation is yet more severely
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Table 3: Some varied scenarios.
Doses 1 2 3 4 5 6
Scenario 1 0.20 0.26 0.28 0.3 0.35 0.50
PCS
SP-CRM 49.4 21.5 13.2 9.6 5.4 0.6
CRM 48.1 19.5 14.3 11.2 6.0 0.6
TR
SP-CRM 47.4 20.6 13.5 9.1 7.0 2.1
CRM 47.6 17.6 14.1 10.7 7.6 2.2
Scenario 2 0.05 0.10 0.20 0.35 0.50 0.70
PCS
SP-CRM 2.3 22.7 54.0 19.7 01.2 0.0
CRM 02.4 22.2 53.9 20.2 01.3 0.0
TR
SP-CRM 10.8 24.3 39.0 19.0 05.9 00.7
CRM 12.3 22.1 37.7 20.4 06.4 00.8
Scenario 3 0.01 0.02 0.05 0.09 0.18 0.40
PCS
SP-CRM 0.0 0.2 2.8 20.3 59.2 17.3
CRM 0.0 0.1 3.4 21.8 58.4 16.1
TR
SP-CRM 4.6 6.0 10.5 19.9 40.7 17.9
CRM 4.9 5.3 9.7 20.7 40.1 19.0
Scenario 4 0.01 0.02 0.05 0.11 0.14 0.21
PCS
SP-CRM 0.0 0.1 3.2 15.7 31.0 49.8
CRM 0.0 0.1 3.4 15.5 31.2 49.6
TR
SP-CRM 4.6 5.8 10.8 16.7 26.7 35.1
CRM 4.9 5.3 10.2 16.7 25.9 36.0
Scenario 5 0.0 0.0 0.16 0.3 0.35 0.4
PCS
SP-CRM 0.0 2.3 51.7 31.5 11.1 3.2
CRM 0.0 3.5 46.7 33.6 12.6 3.6
TR
SP-CRM 4.0 11.8 40.3 24.3 13.7 5.8
CRM 4.7 11.0 36.3 26.7 14.5 6.5
Scenario 6 0.0 0.0 0.0 0.23 0.3 0.35
PCS
SP-CRM 0.0 0.0 10.2 56.8 23.6 9.2
CRM 0.0 0.0 10.5 52.3 26.9 10.2
TR
SP-CRM 4.0 4.0 19 38.8 22.8 11.1
CRM 4.0 4.0 16.9 37.8 24.4 12.7
tested and struggles to accommodate a slope in the neighbourhood of the MTD that is a
strain to ﬁt, SP-CRM shows clearly superior performance, both as measured by PCS and as
measured by TR. The SP-CRM gains its advantage from the ﬂexibility of the prior model that
can readjust to each observation. The same argument underlies its asymptotic performance
and its adaptability to those situations that appear far removed from the model. In order to
conﬁrm this impression, we randomly generated scenarios by making use of order statistics
of quasi-uniform variates (see ﬁgure 5). For this purpose the following algorithm, called the
pseudo-uniform scenario is used.
 The MTD is selected uniformly from a range of doses D: MTD ∼ UD ; resulting in the
value k.
18
http://biostats.bepress.com/cobra/art116
50 100 150 200
50
55
60
65
patient's number (n)
% o
f co
rrec
t re
com
me
nda
tion
Figure 4: For scenario 6, (PCS) as a function of the number of included patients in the study.
: SP-CRM ; ×: CRM.
 We randomly select an upper bound Bs = α + (1 − α) ×M ; M is a random variable
having a Beta law depending on the MTD and the number of dosesm: M ∼ B(max{m−
k; 0.5}, 1).
 The random scenario β has the law of an ordered sample of m uniform laws on [0, Bs]
conditioned by the event {MTD = k}.
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(a) Sample under the pseudo-uniform algorithm
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(b) Sample under Λ
Figure 5: Scenarios tested and scenarios generated by the prior.
The second point downweights the importance of the more extreme scenarios in which the
toxic probabilities following the MTD rise very sharply. Such scenarios can still be sampled
but less frequently. Sampling of the law M is natural; indeed when we have 6 doses and the
MTD is located at level 2, Bs is the maximum of 4 uniform laws on [α, 1]. Table 4 compares
the performance of the CRM and its semi-parameteric version over the set of 100 000 randomly
generated scenarios. Three additional criteria enabling comparison are introduced. (TR(a, b))
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is the percentage of patients treated at doses a and b (see the deﬁnition 3.2); (∆) is the mean
of the diﬀerence between the toxic rates at which patients are treated and the toxicity at the
MTD. The ﬁfth criteria (R-∆) is an index based on the statistic (∆) relative to that value
obtained by the optimal design (O'Quigley et al., 2002). The optimal design is based on the
idea of complete and incomplete information. We can use it sequentially, in a theoretical
setting, to provide a running best estimate of the MTD, the level at which we would like
to treat the next included patient in the study. In order to maintain comparability, at least
early on, we constrain the optimal design to similar behaviour such as that imposed on the
CRM, i.e., only increases in level by one level at a time. This helps provide a reference for the
criterion (∆) : ∆(Opt) = 9.75. The base reference is calculated for the CRM.
R-∆(M) = ∆(M)−∆(OPT)
∆(CRM)−∆(OPT) (11)
As R-∆ gets closer to 0, all the more the considered method gets close to the optimal design.
In all categories, the SP-CRM obtains the best results (Table 4). Regarding the criteria (∆),
Table 4: Comparison from a sample scenario (size=100 000).
Criterion PCS TR TR(a,b) ∆ R-∆
CRM 50.43 39.23 59.68 10.05 1.0
SP-CRM 51.45 39.56 60.22 9.93 0.6
SPM(0, 1/10, 1/3, 40) 51.16 39.19 59.80 10.12 1.23
the diﬀerence between the SP-CRM and the optimal method is 40% smaller than that which
obtains when comparing the CRM to the optimal. This signiﬁcant gain can be explained
in part by the fact that we are very close to the performance of the optimal method. The
parametrisation SPM(0, 1/10, 1/3, 40) from Section 2.2 obtains good results, even if its
distance to the optimal method looks slightly greater than that for the CRM. This leads us to
conclude that very simple parametrisations of SP-CRM can attain comparable performance
to those of the CRM, even in cases where the CRM is considered to be near optimal (Tian,
2016).
In these simulations, it is important to keep in mind that our goal was to emulate as best we
could the behaviour of the CRM. Since this can be accomplished we can conclude that we do no
worse than the CRM. However, the greater ﬂexibility allows us to do better in those particular
cases that prove thorny for the CRM since the explanation for the awkward behaviour here
is the strong parametrisation of the CRM, a feature that is greatly relaxed in SP-CRM. It
remain to study the great range of SPM parametrisation under diﬀerent circumstances. The
posterior Πn on the doses suggests some avenues of exploration for estimating the MTD by
groups of doses which may show itself to be of value when we move beyond Phase I to the
Phase I/II setting. In Figure 6 , the target is α = 0.2 and the MTD is located between 3
and 4. At the end of the trial the posterior puts 81% of its mass over these two doses. In
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(b) The ﬁnal posterior Π.
Figure 6: A balanced scenario: β = (0.04, 0.08, 0.16, 0.24, 0.35, 0.45).
this article we have not presented any results concerning SPM and methods other than the
CRM. Such comparisons can be readily carried out both in theory and in practice leading to
improvements on methods currently in use. We study this more deeply in a separate paper.
Conclusion and perspectives
The central feature of the SPM is the direct modelling of the key parameter of interest, the
dose itself, structured around a regression function that is not fully speciﬁed. The approach
is expressed via a hierarchical Bayesian structure. So far, we have not tried to increase the
ﬂexibility of the usual prior as a way to better deal with poor model speciﬁcation. Instead
we replace the model by a prior that we call the prior model. The topological support of this
is indexed by the parameter of main interest, the MTD. From the asymptotic standpoint, we
no longer seek to obtain convergence on the set of posterior laws, but only on the particular
law surrounding the parameter of interest, the MTD. This, albeit small, change in emphasis
leads to improved asymptotic behaviour. In particular we obtain the almost sure convergence
of the estimator of the MTD built on the observations obtained by the method.
As a by-product we obtain much more and we note that the generalization is suﬃciently
ﬂexible to allow it to include almost all of the currently used model-based designs as special
cases. Here we have applied the generalization to the speciﬁc case of the CRM which is a
strongly parametrized method. We are currently working on doing the same thing for the
CCD, the mTPI and the BOIN methods, all of which can be seen to be less parametric since
they do not explicitly model the relation Y ≈ f(X). All of these methods achieve good
performance both in the treatment of patients and in the accurate locating of the MTD.
Being able to put them under a single umbrella - semi-parametric dose ﬁnding methods - will
enable us to better study the diﬀerences and the similarities between them and, ultimately,
to construct improvements. The SPM framework allows for theoretical study, the results of
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which will then apply to all of these special cases. Furthermore, the SPM can be used in its
own right as a method, as it stands, and our theoretical and simulation based investigations
suggest that it is at least as good, and in most cases better, than all the methods we have
already tested.
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